Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved

被引：3
|
作者：
Huynh, Karina
机构：
[1] Nature Reviews Cardiology,
来源：
NATURE REVIEWS CARDIOLOGY | 2021年 / 18卷 / 11期
关键词：
D O I：
10.1038/s41569-021-00627-z
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：737 / 737
页数：1
相关论文
共 50 条
  • [1] Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved
    Karina Huynh
    [J]. Nature Reviews Cardiology, 2021, 18 : 737 - 737
  • [2] Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
    Boehm, Michael
    Anker, Stefan
    Mahfoud, Felix
    Lauder, Lucas
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Brueckmann, Martina
    Saloustros, Ilias
    Schueler, Elke
    Wanner, Christoph
    Zannad, Faiez
    Packer, Milton
    Butler, Javed
    [J]. EUROPEAN HEART JOURNAL, 2023, 44 (05) : 396 - 407
  • [3] Uric Acid and Treatment With Empagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF): the EMPEROR-Preserved Trial
    Green, Jennifer
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2023, 142 : S25 - S25
  • [4] EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and CKD
    Zannad, Faiez
    Kraus, Bettina J.
    Zeller, Cordula
    Pocock, Stuart
    Packer, Milton
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Anker, Stefan D.
    Butler, Javed
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : B3 - B3
  • [5] Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of blood pressure: the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, J.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Abdin, A.
    Mahfoud, F.
    Brueckmann, M.
    Saloustros, I.
    Schueler, E.
    Ponikowski, P.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Anker, S. D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 132 - 132
  • [6] Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, J.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Abdin, A.
    Mahfoud, F.
    Brueckmann, M.
    Gollop, N. D.
    Iwata, T.
    Ponikowski, P.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Anker, S. D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 131 - 132
  • [7] EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and Chronic Kidney Disease
    Wanner, Christoph
    [J]. INTERNIST, 2022, 63 (SUPPL 3): : 349 - 349
  • [8] Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial
    Packer, Milton
    Zannad, Faiez
    Butler, Javed
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Brueckmann, Martina
    Zeller, Cordula
    Hauske, Sibylle
    Anker, Stefan D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (10) : 1798 - 1799
  • [9] HFpEF management and implication of EMPEROR-Preserved in clinical practice: Insights from Indian cardiologists
    Mate, P. S.
    Lokesh, R. V.
    Patel, K.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 190 - 191
  • [10] EMPAGLIFLOZIN IN HEART FAILURE WITH A PRESERVED EJECTION FRACTION ≥50%: RESULTS FROM THE EMPEROR-PRESERVED CLINICAL TRIAL
    Yousef, Zaheer
    [J]. HEART, 2022, 108 : A79 - A80
12345